Vascular Biogenics Ltd. (NASDAQ:VBLT)’s share price fell 3.4% during mid-day trading on Wednesday . The stock traded as low as $3.89 and last traded at $3.94, with a volume of 283,617 shares. The stock had previously closed at $4.08.

Several brokerages have recently issued reports on VBLT. Zacks Investment Research downgraded Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th. Roth Capital reiterated a “buy” rating and set a $22.00 price objective on shares of Vascular Biogenics in a research report on Thursday, June 9th. HC Wainwright began coverage on Vascular Biogenics in a research report on Tuesday, June 28th. They set a “buy” rating and a $11.00 price objective for the company. Chardan Capital reiterated a “buy” rating on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and set a $14.00 price objective on shares of Vascular Biogenics in a research report on Tuesday, June 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $16.50.

The firm has a 50 day moving average price of $4.27 and a 200-day moving average price of $3.65. The stock’s market capitalization is $88.78 million.

Vascular Biogenics (NASDAQ:VBLT) last released its earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.21). Analysts predict that Vascular Biogenics Ltd. will post ($0.82) EPS for the current fiscal year.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.